Fears Of Recession Mount As Coronavirus Declared A Pandemic
Biopharma Determined To Maintain Clinical Trials, Drug Launches
Executive Summary
Investor sentiment still backing growth for pharma and biotech sectors, but the length and severity of COVID-19's impact globally has yet to be seen.
You may also be interested in...
Antibodies Taken From Recovered Coronavirus Patient Could Yield Therapies
Funded by the US government since March 2018, the Vancouver-based company aims to have an antibody therapy ready for clinical trials within four months.
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.
AstraZeneca’s Next-Gen PARP Inhibitor Hints At Better Safety And Efficacy In Breast Cancer
Early signs of improved safety and efficacy should set up PARP1 inhibitor for potential combinations and future broader use, but the true extent of its benefits remain to be seen.